Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Jansen

Showing results (1001-1010 of 1,087) with videos related to

Pageof 109
Sort By:
Plos One|July 30, 2024
Genome wide association study of clinical duration and age at onset of sporadic CJDHolger Hummerich, Helen Speedy, Tracy Campbell, et al.
Science Immunology|August 12, 2022
Immunodeficiency, autoimmunity, and increased risk of B cell malignancy in humans with <i>TRAF3</i> mutationsWilliam Rae, John M Sowerby, Dorit Verhoeven, et al.
Leukemia|July 18, 2013
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) studyJ V Jovanovic, A Ivey, A M Vannucchi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2018
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapyLinda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
The Lancet. Digital Health|October 27, 2023
A multi-platform approach to identify a blood-based host protein signature for distinguishing between bacterial and viral infections in febrile children (PERFORM): a multi-cohort machine learning studyHeather R Jackson, Judith Zandstra, Stephanie Menikou, et al.
Blood|November 2, 2022
Germ line DDX41 mutations define a unique subtype of myeloid neoplasmsHideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, et al.
The Lancet. Oncology|October 24, 2018
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
Blood|July 3, 2024
Molecular taxonomy of myelodysplastic syndromes and its clinical implicationsElsa Bernard, Robert P Hasserjian, Peter L Greenberg, et al.
Leukemia|January 31, 2024
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trialA A van de Loosdrecht, E M P Cremers, C Alhan, et al.
Blood|April 30, 2024
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromesMaria Sirenko, Elsa Bernard, Maria Creignou, et al.
Pageof 109

Showing results (1001-1010 of 1,087) with videos related to

Sort By:
Pageof 109
Plos One|July 30, 2024
Genome wide association study of clinical duration and age at onset of sporadic CJDHolger Hummerich, Helen Speedy, Tracy Campbell, et al.
Science Immunology|August 12, 2022
Immunodeficiency, autoimmunity, and increased risk of B cell malignancy in humans with <i>TRAF3</i> mutationsWilliam Rae, John M Sowerby, Dorit Verhoeven, et al.
Leukemia|July 18, 2013
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) studyJ V Jovanovic, A Ivey, A M Vannucchi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2018
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapyLinda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
The Lancet. Digital Health|October 27, 2023
A multi-platform approach to identify a blood-based host protein signature for distinguishing between bacterial and viral infections in febrile children (PERFORM): a multi-cohort machine learning studyHeather R Jackson, Judith Zandstra, Stephanie Menikou, et al.
Blood|November 2, 2022
Germ line DDX41 mutations define a unique subtype of myeloid neoplasmsHideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, et al.
The Lancet. Oncology|October 24, 2018
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
Blood|July 3, 2024
Molecular taxonomy of myelodysplastic syndromes and its clinical implicationsElsa Bernard, Robert P Hasserjian, Peter L Greenberg, et al.
Leukemia|January 31, 2024
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trialA A van de Loosdrecht, E M P Cremers, C Alhan, et al.
Blood|April 30, 2024
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromesMaria Sirenko, Elsa Bernard, Maria Creignou, et al.
Pageof 109